Karvy Stock Broking target on GLAXO
Date: 19-May-20
Broker: Karvy Stock Broking
Price @ Call: 1390.74
Target: 1292
Recommendation: SELL
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
GLAXO
1,380.35
+7.4 (0.54%)
Updated 03:29 05/06 IST
GLAXO Buy or Sell - FrontPage Forums
0 Users have submitted 0 trade ideas of Rs. 0 for GLAXO
Disclaimer0% Bullish
0% Bearish
GLAXO Ratings
Long term GLAXO rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
3/5 (1 Ratings)
Find answers to all your questions on live GLAXO message board: Is GLAXO buy or sell? Should I buy GLAXO shares? Why are GLAXO shares falling? Should I invest in GLAXO stock?
GLAXO Share Price Discussion
Reputation: 26,385 • May 19 1:37 AM
*Result Highlight*
Glaxosmithkline Pharmaceuticals Ltd. Q4 Cons: Net profit down -6% at Rs. 138.07 cr. Vs Rs. 146.81 cr. (YoY) and Revenue up 3.3% at Rs. 775.8 cr. Vs Rs. 750.81 cr. (YoY)
Board of Directors recommend a Dividend of Rs 40 per equity share of face value of Rs.10 eac...
Read more...
3
Reply
Reputation: 3,179 • May 18 2:18 AM
GlaxoSmithKline Pharma Q4 net profit declines 6% to Rs 138 crore
For the fiscal year ended March this year, the company posted a net profit of Rs 93.20 crore as against Rs 445.39 crore in the previous fiscal, the filing said.
For the fiscal year ended March this year, the company posted a net profit of Rs 93.20 crore as against Rs 445.39 crore in the previous fiscal, the filing said.
Moneycontrol
Like
Reply
Reputation: 3,179 • May 18 2:08 AM
Trade Setup for Tuesday: Top 15 things to know before Opening Bell
Key support level for Nifty is placed at 8,700.57, followed by 8,577.88. If the index moves up, key resistance levels to watch out for are 9,052.12 and 9,280.98.
Key support level for Nifty is placed at 8,700.57, followed by 8,577.88. If the index moves up, key resistance levels to watch out for are 9,052.12 and 9,280.98.
Moneycontrol
Like
Reply
Reputation: 13,291 • May 6 11:06 AM
Sources :
Glaxo to sell HUL shares via Block deals tomorrow
Deal likely at Rs 1850-1950 per share
Glaxo to sell nearly 6% stake in HUL
Glaxo looks to raise over Rs 25,000 crores via HUL block deal
Like
Reply (3)
Latest replies
Yes sir so tomorrow its a red for HUL
everyday is red for HUL HAHAHA
😂😂😂
Reputation: 3,179 • May 5 12:58 PM
Hot Stocks | Glaxo Pharma, M&M, Tata Comm three buy ideas for short term
In the week gone by, Nifty took out the crucial resistance of 9,390, which will interchange its role as immediate resistance.
In the week gone by, Nifty took out the crucial resistance of 9,390, which will interchange its role as immediate resistance.
Moneycontrol
Like
Reply
Reputation: 3,179 • Apr 15 12:38 PM
Hot Stocks | Three stock ideas for the short term
By surpassing the resistance of 8,600 in the previous week, Nifty also confirmed the bullish inverse head and shoulder pattern breakout on the daily line charts.
By surpassing the resistance of 8,600 in the previous week, Nifty also confirmed the bullish inverse head and shoulder pattern breakout on the daily line charts.
Moneycontrol
Like
Reply
Reputation: 3,179 • Apr 12 6:33 AM
USFDA asks companies to remove ranitidine products; will Indian regulator review its stand?
The USFDA is investigating presence N-Nitrosodimethylamine, a probable cancer causing impurity in ranitidine products.
The USFDA is investigating presence N-Nitrosodimethylamine, a probable cancer causing impurity in ranitidine products.
Moneycontrol
Like
Reply
Reputation: 3,179 • Mar 19 10:18 AM
Coronavirus pandemic | Pharma companies ask sales representatives to work from home
India's largest drug maker Sun Pharma which has field force 9,500 plus covering over 400,000 doctors in every nook and corner of the country said it is encouraging employees in the field globally to work from home.
India's largest drug maker Sun Pharma which has field force 9,500 plus covering over 400,000 doctors in every nook and corner of the country said it is encouraging employees in the field globally to work from home.
Moneycontrol
Like
Reply
Reputation: 3,179 • Mar 9 2:23 AM
Pharma sales see rebound in February on back of respiratory drugs
Eight of the top 10 therapies registered a growth of more than 10 percent.
Eight of the top 10 therapies registered a growth of more than 10 percent.
Moneycontrol
Like
Reply
Reputation: 3,179 • Mar 5 3:43 AM
24 companies in BSE500 index reported net loss in Q3; what should you do with the stocks?
Among the top 500 companies, over 20 companies turned loss-making in the December quarter, data from AceEquity showed
Among the top 500 companies, over 20 companies turned loss-making in the December quarter, data from AceEquity showed
Moneycontrol
Like
Reply
Reputation: 3,179 • Mar 4 11:18 AM
MNC drug body OPPI names Sharad Tyagi as President
Tyagi is currently Managing Director, Boehringer Ingelheim India. He replaces A Vaidheesh of GSK.
Tyagi is currently Managing Director, Boehringer Ingelheim India. He replaces A Vaidheesh of GSK.
Moneycontrol
Like
Reply
Reputation: 3,179 • Mar 4 9:03 AM
Sridhar Venkatesh appointed as GSK India MD, VP
Venkatesh has more than 24 years of diverse experience in pharmaceuticals and healthcare, and has a strong track record of success in multiple roles within GSK, it added.
Venkatesh has more than 24 years of diverse experience in pharmaceuticals and healthcare, and has a strong track record of success in multiple roles within GSK, it added.
Moneycontrol
Like
Reply
Reputation: 3,179 • Feb 10 12:28 PM
Ranitidine recall forces GSK to alter Indian market strategy
GSK had initiated global voluntary recall of Ranitidine in September 2019, following reports of a probable cancer causing impurity called N‐nitrosodimethylamine (NDMA).
GSK had initiated global voluntary recall of Ranitidine in September 2019, following reports of a probable cancer causing impurity called N‐nitrosodimethylamine (NDMA).
Moneycontrol
Like
Reply
Reputation: 26,385 • Feb 6 11:17 AM
GSK announces sale of Vemagal plant; takes Rs 640 crore hit on account of Zinetac recall - Times of India
Times of India brings the Latest & Top Breaking News on Politics and Current Affairs in India & around the World, Cricket, Sports, Business, Bollywood News and Entertainment, Science, Technology, Health & Fitness news & opinions from leading columnists.
Times of India brings the Latest & Top Breaking News on Politics and Current Affairs in India & around the World, Cricket, Sports, Business, Bollywood News and Entertainment, Science, Technology, Health & Fitness news & opinions from leading columnists.
The Times of India
Bad News for Pharmaceutical sector GlaxoSmithKline (GSK) Pharma - Bangalore
Yesterday night gave a very big Dinner in 5 star hotel to all Bangalore Employee & at the end of Dinner
GSK handed Termination Letter. With 6 months Salary Cheque.
GSK Pharma - Bangalore plant is clos...
Read more...
Like
Reply
Reputation: 3,179 • Feb 5 11:13 AM
XLRI completes final placement in two days, average salary up by Rs 2 lakh at Rs 24.3 lakh pa
The final recruitment process saw participation from 108 recruiters with 362 domestic and international offers.
The final recruitment process saw participation from 108 recruiters with 362 domestic and international offers.
Moneycontrol
Like
Reply
Reputation: 3,179 • Feb 4 5:13 AM
GSK Pharma share price tanks 10% to hit 3-month low after Q3 loss of Rs 661 crore
The results were impacted due to voluntary global recall of ranitidine products, including Zinetac, said GlaxoSmithKline Pharmaceuticals Managing Director A Vaidheesh.
The results were impacted due to voluntary global recall of ranitidine products, including Zinetac, said GlaxoSmithKline Pharmaceuticals Managing Director A Vaidheesh.
Moneycontrol
Like
Reply
Reputation: 14,255 • Feb 4 4:38 AM
GlaxoSmithKline Pharma plunges 13% on net loss of Rs 661 crore in Q3 - Business Standard
04-Feb-2020 09:53:09 AM
Shares of GlaxoSmithKline Pharmaceuticals tanked 13 per cent to Rs 1,429 on the BSE on Tuesday after the company reported a consolidated net loss of Rs 661 crore for ...
Read more...
Like
Reply
Reputation: 3,179 • Feb 3 2:18 AM
GlaxoSmithKline Pharma posts net loss of Rs 661.16cr for December quarter
The company had posted a net profit of Rs 113.67 crore for the corresponding period of the previous financial year, GlaxoSmithKline Pharmaceuticals said in a filing to the BSE.
The company had posted a net profit of Rs 113.67 crore for the corresponding period of the previous financial year, GlaxoSmithKline Pharmaceuticals said in a filing to the BSE.
Moneycontrol
Like
Reply
Reputation: -15,697 • Dec 24 8:55 AM
GSK PHARMA: LIC SELLS 34 LAKH SHARES (2% EQUITY) OF CO VIA OPEN MARKET ON DECEMBER 19
Like
Reply
Reputation: 1,115 • Nov 15 2:50 AM
For the Job and Part time Traders 😘
This is one more simple example of Simplicity with out Charts ..
Glaxo bullish 1350 and see high 1703 in just 15 days so be in trend always
Like
Reply
Reputation: 7,516 • Oct 22 10:48 AM
Glaxo Pharma – Q2 FY20 (Unaudited – Cons.)
Share price – 1435
Total revenue from operations at 882.02 Cr
816.31 Cr (8.03%) YoY | 787.91 Cr (11.92%) QoQ
Six month ended revenue: 1669.9 Cr Vs. 1551.9 Cr (7.02%)
Net Profit of 502.7 Cr
100.8 Cr (402.43%) YoY 113.5 (345.07%) QoQ
Six...
Read more...
1
Reply
Reputation: 3,179 • Oct 22 10:43 AM
GSK Pharma Q2 profit at Rs 503 cr
Revenue from operations stood at Rs 882.02 crore for the quarter under review as against Rs 816.31 crore in the same period a year ago.
Revenue from operations stood at Rs 882.02 crore for the quarter under review as against Rs 816.31 crore in the same period a year ago.
Moneycontrol
Like
Reply
Reputation: 3,179 • Oct 9 1:38 AM
Indian pharma market sees growth of 11.5% in Q2FY20
The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
Moneycontrol
Like
Reply
Reputation: 3,179 • Oct 9 11:08 AM
Indian pharma market registers growth of 11.5% in Q2FY20
The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 30 7:53 AM
Ranitidine controversy: Which Indian pharma companies stand to lose?
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 26 4:03 AM
GSK Pharma slips 5% after halting sale of acidity medicine Zinetac, other ranitidine products
The company has made the decision to initiate a voluntary recall of Zinetac Tablets 150 mg and 300 mg products manufactured in India.
The company has made the decision to initiate a voluntary recall of Zinetac Tablets 150 mg and 300 mg products manufactured in India.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 26 1:58 AM
Stocks in the news: DHFL, Cipla, GSK Pharma, Sterlite Tech, Future Enterprises, CG Power, SRF
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 26 1:43 AM
Stocks in the news: DHFL, Cipla, GSK Pharma, Adani Enterprises, Future Enterprises, CG Power, SRF
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 26 1:18 AM
Stocks in the news: DHFL, Cipla, GSK Pharma, Adani Enterprises, Future Enterprises, Sterlite Tech
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 25 2:18 AM
Trade Setup for Thursday: Top 15 things to know before Opening Bell
According to the pivot charts, key support level for Nifty is placed at 11,382.53, followed by 11,324.87. If the index starts moving up, key resistance levels to watch out for are 11,531.43 and 11,622.67.
According to the pivot charts, key support level for Nifty is placed at 11,382.53, followed by 11,324.87. If the index starts moving up, key resistance levels to watch out for are 11,531.43 and 11,622.67.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 25 12:28 PM
GSK suspends Ranitidine distribution in India, regulators seek drug testing data from pharma cos
Sources within pharma industry told Moneycontrol that Dr Reddy’s and Saraca Laboratories are two big suppliers of the Ranitidine active pharmaceutical ingredient (API) globally, from which most other companies source the API to formulate the drug.
Sources within pharma industry told Moneycontrol that Dr Reddy’s and Saraca Laboratories are two big suppliers of the Ranitidine active pharmaceutical ingredient (API) globally, from which most other companies source the API to formulate the drug.
Moneycontrol
Like
Reply
Reputation: 1,414 • Sep 10 4:25 AM
Like
Reply (1)
Latest replies
FROM 1333 TO 1400 (67 POINTS) PROFIT (+5% UP)
Reputation: 3,179 • Sep 9 11:33 AM
Pharma companies cheer good monsoon as demand for anti-infective drugs rises
Anti-infective drugs grew at 15.3 percent YoY in August, compared to Indian pharmaceutical market growth of 9.4 percent.
Anti-infective drugs grew at 15.3 percent YoY in August, compared to Indian pharmaceutical market growth of 9.4 percent.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 3 12:13 PM
Government scrambles to address shortage of rabies vaccine after GSK exit
Sources within the vaccine industry said that one of the main reasons for the current shortage was due to the exit of Chiron Behring Vaccines, a unit of GlaxoSmithKline (GSK).
Sources within the vaccine industry said that one of the main reasons for the current shortage was due to the exit of Chiron Behring Vaccines, a unit of GlaxoSmithKline (GSK).
Moneycontrol
Like
Reply
Reputation: 3,179 • Aug 21 3:29 AM
Focus on selective products, therapies starting to pay dividends: GSK Pharma
Vaidheesh hinted at new launches such as a vaccine (Bexsero) to protect infants against Meningitis B and a new drug to treat autoimmune disorders
Vaidheesh hinted at new launches such as a vaccine (Bexsero) to protect infants against Meningitis B and a new drug to treat autoimmune disorders
Moneycontrol
Like
Reply
Reputation: 3,179 • Aug 7 9:38 AM
Hold GlaxoSmithKline Consumer Healthcare; target of Rs 7972: Prabhudas Lilladher
Prabhudas Lilladher recommended hold rating on GlaxoSmithKline Consumer Healthcare with a target price of Rs 7972 in its research report dated August 05, 2019.
Prabhudas Lilladher recommended hold rating on GlaxoSmithKline Consumer Healthcare with a target price of Rs 7972 in its research report dated August 05, 2019.
moneycontrol.com
Like
Reply
Reputation: 3,179 • Jul 15 2:38 AM
GSK to focus on 20 brands, 5 disease segments to drive India growth
Like
Reply
Reputation: 3,179 • Jul 10 7:53 AM
MNCs may delist if govt imposes 35% public shareholding norms; 14 stocks in focus
Like
Reply
Reputation: 3,179 • May 24 7:13 AM
CCI approves GSK, Pfizer consumer healthcare JV formation
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
GLAXO Share Price - Technicals
- NewsBotMay 5 12:58 PMHot Stocks | Glaxo Pharma, M&M, Tata Comm three buy ideas for short termMoneycontrolNewsBotApr 15 12:38 PMHot Stocks | Three stock ideas for the short termMoneycontrolNewsBotApr 12 6:33 AMUSFDA asks companies to remove ranitidine products; will Indian regulator review its stand?MoneycontrolNewsBotMar 19 10:18 AMCoronavirus pandemic | Pharma companies ask sales representatives to work from homeMoneycontrolNewsBotMar 9 2:23 AMPharma sales see rebound in February on back of respiratory drugsMoneycontrolNewsBotMar 5 3:43 AM24 companies in BSE500 index reported net loss in Q3; what should you do with the stocks?MoneycontrolNewsBotMar 4 11:18 AMMNC drug body OPPI names Sharad Tyagi as PresidentMoneycontrolNewsBotMar 4 9:03 AMSridhar Venkatesh appointed as GSK India MD, VPMoneycontrolNewsBotFeb 10 12:28 PMRanitidine recall forces GSK to alter Indian market strategyMoneycontrolNewsBotFeb 5 11:13 AMXLRI completes final placement in two days, average salary up by Rs 2 lakh at Rs 24.3 lakh paMoneycontrol
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.